through the Integration of Biosensing and AI
Ultra-Precision Sensing Technology
Model BA200
Designed for non-invasive point-of-care assessment of airway inflammation, this device combines high-sensitivity biosensor technology (0.1 ppb) with full ATS/ERS compliance. It delivers multi-parameter results—FeNO, CaNO, FnNO—in under one minute, while a patented dual-channel design ensures complete protection against cross-contamination.
More
Driven by a passion for innovation and a commitment to excellence, desire to maintain high levels of innovation, knowledge, technical expertise, service.
Committed to providing solutions for respiratory diseases, cardiovascular diseases and metabolic diseases
Become a global provider in comprehensive chronic disease solution for both professional segment and homecare.
Fractional exhaled nitric oxide (FeNO) has become an indispensable tool in respiratory medicine. As a non-invasive biomarker of Type-2 airway inflammation, FeNO testing is now widely used in asthma diagnosis, monitoring, and treatment gui...
Introduction Fractional exhaled nitric oxide (FeNO) has become a cornerstone in the management of asthma and other airway diseases. As a non‑invasive biomarker of type‑2 inflammation, it helps clinicians diagnose eosinophilic asthma, pr...
Asthma is one of the most common chronic respiratory conditions worldwide, affecting an estimated 260 million people globally. It is a lifelong condition characterized by chronic airway inflammation that makes breathing difficult. While a...
Please complete the form to contact our team